All In Biotech

Drug Trial Radar · NCT06299111

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

195

Actual

Start

Sep 20, 2024

Primary completion

Mar 27, 2026

Study completion Mar 27, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Venous Thromboembolism

Interventions

  • REGN9933Drug

    Intravenous (IV) single dose administered

  • REGN7508Drug

    IV single dose administered

  • PlaceboDrug

    IV single dose administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of confirmed VTE per central reading center (CRC) reviewTime frame: Through Day 14
  2. Incidence of treatment-emergent adverse event (TEAEs)Time frame: Up to Day 100
  3. Severity of TEAEsTime frame: Up to Day 100

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan Kettering

    New York, New York

  • Sveta Sofia Hospital

    Sofia, Bulgaria

  • Juravinski Hospital

    Hamilton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Lakeridge Health

    Oshawa, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • Hadassah University Medical Center

    Jerusalem, Israel

  • Lanadio Medical Center

    Netanya, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, Israel

  • Soroka University Medical Center

    Beersheba, Southern District, Israel

  • Arensia Research Clinic

    Bucharest, Romania

  • Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca

    Cluj-Napoca, Romania

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • University hospital Southampton

    Southampton, Hampshire, United Kingdom

  • Cardiff and Vale University Health Board - University Hospital Wales

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.